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discussed, including diuretic-induced hyponatremia, adre-
nal and pituitary insufficiency, the syndrome of inappropri-
ate antidiuresis, cerebral salt wasting, and exercise-associ-
ated hyponatremia. The treatment of hyponatremia is 
reviewed from simple saline solutions to the recently intro-
duced vasopressin receptor antagonists, including their 
promises and limitations. Given the persistently high rates of 
hospital-acquired hyponatremia, the importance of improv-
ing the management of hyponatremia seems both neces-
sary and achievable.  Copyright © 2008 S. Karger AG, Basel 
 Introduction  
 Hyponatremia is the most commonly encountered 
electrolyte disorder in clinical medicine, and occurs in 
approximately one of every three hospitalized patients 
 [1] . Hyponatremia is defined as a decreased serum sodi-
um concentration (usually below 136 mmol/l) and always 
implies that there is water in excess of sodium. The pres-
ence of hyponatremia is therefore primarily a reflection 
of a disturbance in water rather than sodium balance, al-
though several interactions between the two regulatory 
systems exist. Because the definition of hyponatremia is 
based on a concentration, it does not provide information 
on the filling of the extracellular fluid volume (ECF) in 
 Key Words 
 Hyponatremia   Vasopressin   Water balance regulation 
 Abstract 
 The complexity of hyponatremia as a clinical problem is like-
ly caused by the opposite scenarios that accompany this 
electrolyte disorder regarding pathophysiology (depletional 
versus dilutional hyponatremia, high versus low vasopressin 
levels) and therapy (rapid correction to treat cerebral edema 
versus slow correction to prevent osmotic demyelination, 
fluid restriction versus fluid resuscitation). For a balanced 
differentiation between these opposites, an understanding 
of the pathophysiology of hyponatremia is required. There-
fore, in this review an attempt is made to translate the phys-
iology of water balance regulation to strategies that improve 
the clinical management of hyponatremia. A physiology-
based approach to the patient with hyponatremia is pre-
sented, first addressing the possibility of acute hyponatre-
mia, and then asking if and if so why vasopressin is secreted 
non-osmotically. Additional diagnostic recommendations 
are not to rely too heavily of the assessment of the extracel-
lular fluid volume, to regard the syndrome of inappropriate 
antidiuresis as a diagnosis of exclusion, and to rationally in-
vestigate the pathophysiology of hyponatremia rather than 
to rely on isolated laboratory values with arbitrary cutoff val-
ues. The features of the major hyponatremic disorders are 
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which sodium is measured. In fact, hyponatremia can oc-
cur in the context of a contracted ECF (hypovolemia), 
normal ECF (normovolemia) or expanded ECF (hyper-
volemia)  [2] . The fact that completely different patho-
physiological settings can present with hyponatremia 
emphasizes the importance of a careful diagnostic ap-
proach in order to select adequate therapy. The reason 
that hyponatremia requires treatment is that the relative 
excess of water lowers serum osmolality (of which sodi-
um is the most important determinant), causing a shift 
of water into cells until new osmotic equilibrium is 
reached. Although hyponatremia will cause all cells to 
swell, brain cell swelling is especially dangerous because 
the rigid box of the skull limits space for expansion. The 
ramifications of hyponatremia for the brain are twofold: 
cerebral edema if hyponatremia develops quickly (acute 
hyponatremia), or osmotic demyelinization if chronic 
hyponatremia is corrected too quickly after brain cells 
have adapted to their hypotonic environment  [2] . The 
complexity of hyponatremia as a clinical problem and the 
opposite choices that are involved (e.g., fluid resuscita-
tion vs. fluid restriction, quick vs. slow correction) some-
times results in inadequate management including de-
layed therapy, iatrogenic damage, and increased health-
care costs  [1, 3] . One solution to this problem could be to 
select a more physiological approach to hyponatremia  [4] . 
Therefore, in this review an attempt is made to translate 
the pathophysiological principles of hyponatremia to 
strategies that may improve its clinical management. 
Bearing this in mind, an overview of the hyponatremic 
disorders and their treatment is given, emphasizing nov-
el insights such as exercise-associated hyponatremia, the 
nephrogenic syndrome of inappropriate antidiuresis, and 
vasopressin receptor antagonists that have recently be-
come available.
 The Pathophysiology of Hyponatremia 
 Water Balance Regulation: The Brain–Kidney 
Connection 
 Water balance regulation depends on an interaction 
between specialized sensors that translate the signals 
they receive (high serum osmolality, low effective circu-
lating volume) to the central release of arginine vasopres-
sin (the antidiuretic hormone) into the circulation, which 
then stimulates water reabsorption in the renal collecting 
duct.  Figure 1 shows how water balance regulation is dis-
turbed during hyponatremia, but also provides an over-
view of the regulatory system during normal physiology. 
Water balance regulation is primarily designed to control 
serum osmolality and to a lesser extent blood volume (va-
sopressin starts to rise after a 1% increment in serum os-
molality vs. a 5–10% decrease in blood volume). The se-
rum osmolality is sensed by osmoreceptors in several 
parts of the brain, including the supraoptic nuclei of the 
hypothalamus, the subfornical organ, and the organum 
vasculosum of the lamina terminalis ( fig. 1 )  [5, 6] . A rise 
in serum osmolality causes water to move through the 
water channels of the osmoreceptor cell membranes, 
which then causes a change in cell volume. This leads to 
an increase in the activity of stretch-inhibited cation 
channels (including the N-terminal variant of the tran-
sient receptor potential vanilloid type-1  [7] ), affecting 
membrane voltage and ultimately the action potential 
discharge  [8] . The accelerated action potential discharge 
causes an influx of calcium through a voltage-gated cal-
cium channel which triggers a cascade of molecular 
events that ultimately leads to the neurosecretion of se-
cretory vesicles containing vasopressin into the blood-
stream ( fig. 1 )  [9] . On the other hand, the carotid sinus 
baroreceptors sense a low effective circulating volume, 
and parasympathetic afferents transfer this signal to the 
vasomotor center, which increases the rate of vasopressin 
secretion by the cells in the paraventricular nuclei ( fig. 1 ). 
Once released into the circulation, vasopressin can acti-
vate three types of G-coupled receptors, including V1a 
(vascular and hepatic), V1b (anterior pituitary), and V2 
(renal collecting duct). The activation of the vasopressin-
2 receptor V2R by vasopressin stimulates an intracellular 
cascade, which ultimately results in the insertion of aqua-
porin (AQP)-2 (AQP2) water channels in the apical mem-
brane ( fig. 2 shows this process by electron microscopy). 
The presence of AQPs in combination with an osmotic 
gradient allows water to move through the principal cell, 
returning to the basolateral bloodstream via the consti-
tutively expressed AQP3 and AQP4 water channels  [10] . 
Vasopressin also increases sodium and urea permeability 
in the collecting duct (by increasing the number of the 
epithelial sodium channel, ENaC, and the urea trans-
porter, UT-A1), thereby maintaining the osmotic and 
medullary interstitial gradients and further stimulating 
antidiuresis  [11] . Short-term control of water permeabil-
ity is achieved through trafficking of AQP2-containing 
vesicles to the apical membrane, whereas long-term con-
trol influences the abundance of the AQP2 protein. The 
molecular machinery of this V2R-AQP2 cascade is in-
creasingly being unraveled. The current understanding 
of this cascade is that stimulation of the V2R by vasopres-
sin activates the Gs adenylyl cyclase system, stimulating 
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cAMP and protein kinase A (PKA), which triggers the 
phosphorylation of many proteins including AQP2  [10] . 
However, several other signaling pathways have been im-
plicated in the V2R-AQP2 cascade, involving for example 
PKA-independent pathways  [12] , calcium-calmodulin 
 [13] , Rho, soluble  N - ethylmaleimide-sensitive factor at-
tachment receptors (SNARE) proteins, cAMP responsive 
element-binding protein (CREB) and extracellular sig-
nal-regulated kinase (ERK)  [13] .
 Hyponatremia: Non-Osmotic Vasopressin Release and 
Its Escape 
 The presence of hyponatremia nearly always implies 
that vasopressin is released non-osmotically, thereby pre-
venting the excretion of electrolyte-free water, and dilut-
ing the serum sodium concentration. For example, An-
derson et al.  [14] showed that non-osmotic vasopressin 
secretion was present in 97% of hyponatremic patients 
studied. Causes of non-osmotic vasopressin release in-
 Fig. 1. The pathophysiology of vasopressin during hyponatremia. 
In the majority of patients, hyponatremia develops because vaso-
pressin is secreted non-osmotically resulting in renal water reab-
sorption. The figure shows the four mechanisms that can cause 
this effect: (1) non-osmotic vasopressin release by the posterior 
pituitary induced by specific stimuli from the paraventricular or 
supraoptic nuclei; (2) ectopic vasopressin production; (3) factors 
that may enhance the renal effects of vasopressin, and, finally, (4) 
a vasopressin-like effect caused by an activating mutation of the 
vasopressin-2 receptor. In addition, details of the hypothalamo-
neurohypophyseal system and the intracellular signaling cascade 
in the renal collecting duct principal cell are shown. The illustra-
tion of the hypothalamo-neurohypophyseal system was adapted 
from Patel and Balk [74], with kind permission. 
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clude a low effective circulating volume, several diseases 
and drugs, and nonspecific stimuli such as anxiety, stress, 
pain, and nausea ( fig. 1 ). Apart from the increased pro-
duction of vasopressin, vasopressin can also be produced 
ectopically (e.g., in small cell lung cancer), its renal effects 
can be enhanced with normal vasopressin levels (e.g., by 
cyclophosphamide), or a vasopressin-like effect can oc-
cur in the absence of vasopressin (e.g., through an acti-
vating mutation of the V2R;  fig. 1 )  [15] . Although many 
of the pathways that influence central non-osmotic vaso-
pressin release are unknown, there is increasing evidence 
for a relationship between high interleukin-6 levels and 
vasopressin release  [16] . Interleukin-6 appears to take the 
same secretory pathway as vasopressin  [17] and interleu-
kin-6 receptors and signal-transducing units exist in the 
hypothalamo-neurohypophyseal system  [18] . We recent-
ly showed a direct relationship between a rise in C-re-
active protein and the development of hyponatremia
 [19] , suggesting that the acute-phase response, perhaps 
through interleukin-6, could explain the established re-
lationship between certain infections and hyponatre-
mia.
 There may have been an evolutionary benefit for the 
non-osmotic release of vasopressin to conserve water 
during times of severe volume depletion or infection. To 
date, however, the non-osmotic release of vasopressin is 
often unwanted (for example because it is paraneoplastic 
or drug-related), and may give rise to the syndrome of 
inappropriate antidiuresis (SIAD). It is important to real-
ize that the actual development of hyponatremia always 
requires the ongoing consumption of water, which in hu-
mans is often socially determined rather than thirst driv-
en (conversely,  it is difficult to induce hyponatremia in 
animals). However, a defense mechanism exists to limit 
the degree of hyponatremia when vasopressin levels are 
persistently high and water is ingested continuously. ‘Es-
cape’ from vasopressin-induced antidiuresis is an impor-
tant physiological response, during which water diuresis 
develops despite high circulating levels of vasopressin 
 [10] . The renal mechanisms of vasopressin escape include 
not only a downregulation of AQP2 (through a combina-
tion of V2R internalization and transcriptional and trans-
lational regulation of AQP2), but also of the epithelial so-
dium channel ENaC and the urea transporter UT-A3, 
which may contribute to a solute diuresis  [20] .
 A Physiology-Based Approach to Hyponatremia 
 Recently, we evaluated the validity and accuracy of the 
existing clinical diagnostic algorithms for hyponatremia 
 [4] which are commonly used in the diagnostic approach 
to hyponatremia. Three main weaknesses were identified 
including a failure to consider acute hyponatremia, a ten-
dency to diagnose SIAD prior to excluding other causes 
of hyponatremia, and too much emphasis on the clinical 
assessment of the ECF  [4] .
A
B
C
 Fig. 2. Immuno-gold localization of aquaporin-2 (AQP2) in renal 
collecting ducts before, during and after stimulation with argi-
nine vasopressin (AVP). Electron microscopy images showing 
immuno-gold localization of the water channel AQP2 in isolated 
perfused tubules of the renal collecting duct principal cell.  A The 
basal condition (pre-AVP, osmotic water permeability 65   m/s) 
with AQP2 mainly localized in vesicles (arrowheads).  B Stimula-
tion with arginine vasopressin (AVP, osmotic water permeability 
454   m/s) and the insertion of AQP2 in the apical plasma mem-
brane (multiple arrows) is illustrated.  C The situation after stimu-
lation with arginine vasopressin (post-AVP, osmotic water per-
meability 204   m/s) with AQP2 again mainly localized in vesi-
cles, including multi-vesicular bodies (MVB). This picture is 
courtesy of Dr. Søren Nielsen (University of Aarhus, Denmark) 
and Dr. Mark Knepper (National Institutes of Health, USA). 
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 To overcome some of these limitations, a more physi-
ology-based approach was proposed, in which the possi-
bility of acute hyponatremia was considered first, and 
subsequently an analysis was made if and why vasopres-
sin levels are elevated.  Figure 3 shows a modified version 
of this algorithm  [4] , while  table 1 summarizes the gen-
eral recommendations. More recently, others have also 
emphasized the importance of recognizing and treating 
acute hyponatremia prior to proceeding with further di-
agnostic evaluation  [21] . Moreover, if time permits, the 
possibilities of pseudohyponatremia and hyperglycemia-
induced hyponatremia should also be considered (by 
measuring serum osmolality and serum glucose), be-
cause these causes of hyponatremia require no or differ-
ent treatment ( fig. 3 A).
 Acute hyponatremia is defined as the development of 
symptomatic hyponatremia of 125 mmol/l or less within 
48 h. A history of polydipsia or another obvious source of 
electrolyte-free water (e.g., hypotonic intravenous fluids) 
often precedes the presentation of acute hyponatremia. 
However, its differentiation from chronic hyponatremia 
remains a challenge because the early symptoms of acute 
hyponatremia are nonspecific (nausea, vomiting, head-
ache, confusion) and the patient usually presents hypo-
natremia without documentation of the previous course 
in serum sodium. Hsu et al.  [22] identified 1,321 patients 
with hyponatremia in a 2-year retrospective study, 11 of 
whom were found to have acute hyponatremia (mean se-
rum sodium 115 mmol/l, average fluid intake 5 liters/
day). They identified low serum urea and uric acid con-
centrations and increased fractional excretions of both as 
biochemical abnormalities accompanying acute hypona-
tremia which were attributed to an effect of acute volume 
expansion  [22] . When assessing acute hyponatremia, it is 
important to note that the venous serum sodium concen-
tration can be appreciably higher than the arterial sodi-
Start diagnostic evaluation and
select therapy appropriate for
cause of hyponatremia
(proceed to Figure 3B and Table 3)
· Severe hyponatremia (≤125 mmol/l)
· Documented as acute (duration <48 h)
· Or with convulsions or coma
Start hypertonic saline
(rise 1–2 mmol/l/h until symptoms abate
and not exceeding 8–12 mmol/l/day)
Hypotonic hyponatremia
Exclude or correct for
Pseudohyponatremia
Hyperglycemia-induced hyponatremia
Serum sodium ≤136 mmol/l
· Mild hyponatremia (125–136 mmol/l)
· Or documented as chronic (duration >48 h)
· And asymptomatic or only mild symptoms
Aim is to correct cerebral edema Aim is to correct hyponatremia
and prevent osmotic demyelination
 Fig. 3.  A Diagnostic approach to hypona-
tremia: first determine the acuity. 
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um concentration (which determines the effect on the 
brain), especially when water absorption is rapid  [23, 
24] .
 Once acute hyponatremia has been dealt with, further 
diagnostic evaluation should take place. In our opinion, 
the next relevant question should be if and if so why va-
sopressin is released non-osmotically. If vasopressin is 
acting, the urine osmolality usually exceeds the serum 
osmolality. However, because hypoosmolality should 
normally lower urine osmolality to below 100 mosm/kg, 
it should be borne in mind that urine osmolalities be-
tween 100 and 300 mosm/kg could still suggest vasopres-
sin action, although other factors such as high water in-
take or low osmotic intake are usually necessary to cause 
overt hyponatremia. The comparison between serum 
and urine osmolality may replace the actual measure-
ment of vasopressin, which is not routinely performed in 
the analysis of hyponatremia.
 If it is likely that vasopressin is acting, several impor-
tant causes of hyponatremia with elevated levels of vaso-
pressin should be considered, including the use of diuret-
ics, pituitary, adrenal and thyroid insufficiency, heart 
Non-renal loss
Diarrhea
Burns
Above diagnoses
excluded or unlikely
Low effective
circulating volume
Heart failure
Liver cirrhosis
Endocrine causes
Hypopituitarism
Adrenal insufficiency
Hypothyroidism
Syndrome of
inappropriate antidiuresis
(Apparent) vasopressin activity?
Urine > serum osmolality
Undetectable or normal vasopressin levels
Unresponsiveness to vasopressin receptor antagonists
Nephrogenic syndrome of inappropriate antidiuresis
(activating mutation of vasopressin-2 receptor)
Reset osmostat
Salt wasting
Cerebral
Renal
Vomiting
Polydipsia and/or impaired water
excretion independent of vasopressin
Low dietary solute intake
Primary polydipsia
Beer potomania
Renal failure
No obvious cause
Perform water loading test
Abnormal Normal
(Thiazide) diuretics?
Yes No
No
Once a diagnosis is
established, proceed to
therapeutic options (Table 3)
 Fig. 3.  B Diagnostic approach to hyponatremia: evaluate if and if so why vasopressin is acting. 
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and liver failure, cerebral and renal salt wasting, and non-
renal sodium loss. In fact, by the definition of Janicic and 
Verbalis  [25] , these causes should all be excluded prior to 
considering the diagnosis of SIAD ( fig. 3 B). Usually, an 
analysis of medication (thiazide use), physical examina-
tion (edema in heart and liver failure), clinical setting (ce-
rebral salt wasting in subarachnoid hemorrhage), symp-
tomatology (vomiting, diarrhea) or laboratory tests (low 
cortisol in adrenal and pituitary insufficiency) are suffi-
cient to steer the differentiation between these hypona-
tremic disorders.
 Of the endocrine disorders associated with hyponatre-
mia, especially primary adrenal insufficiency is often 
missed, possibly because hyperkalemia is absent in a 
third of the cases  [26] , and because random cortisol mea-
surements may be misinterpreted  [27] . Smith et al. [27] 
therefore recommended having a low threshold for per-
forming the short corticotrophin test in patients with un-
explained hyponatremia. Hypopituitarism with second-
ary adrenal insufficiency is another overlooked cause of 
hyponatremia  [28] , and might be differentiated from 
SIAD by the presence of a compensated respiratory alka-
losis (possibly due to subclinical cerebral edema) with a 
low plasma bicarbonate (possibly due to aldosterone de-
ficiency) and low carbon dioxide levels  [29] . The relation-
ship between hypothyroidism and hyponatremia, al-
though described in every textbook, was recently ques-
tioned by Warner et al.  [30] . Although they showed a 
statistical association between hyponatremia and hypo-
thyroidism (for every 10 mU/l rise in thyroid-stimulating 
hormone, serum sodium decreased 0.14 mmol/l), the 
clinical relevance of this association seems minute. If the 
relationship does exist, a low cardiac output (stimulating 
volume-mediated vasopressin release) and/or a low glo-
merular filtration rate (low distal delivery diminishes 
free water excretion) could explain its pathophysiology.
 If other hyponatremic disorders are unlikely or ex-
cluded and SIAD is suspected, a careful analysis should 
be made if the patient is taking any drugs or has any un-
derlying disease that has ever been associated with SIAD 
 [21] . If no obvious cause for SIAD is found, further test-
ing may be necessary by measuring vasopressin and per-
forming a water loading test (which is normal when 
 6 80% of a 15-ml/kg water load is excreted in 4 h)  [31, 32] . 
If vasopressin levels are undetectable and water is re-
tained, this could indicate nephrogenic SIAD due to an 
activating mutation of the V2R, a recently discovered and 
novel cause of hyponatremia  [15] . If vasopressin levels are 
normal and water is also excreted normally, a reset osmo-
stat should be considered. Another clue is that vasopres-
sin-receptor antagonists will not provoke a response in 
both nephrogenic SIAD and reset osmostat ( fig. 3 B).
 Several other parameters in serum and urine may as-
sist in the diagnostic approach to hyponatremia, includ-
ing osmolality, sodium, chloride, potassium, creatinine, 
urea, uric acid, and acid-base ( table 2 ). Our recommenda-
tion is to use these parameters as supportive rather than 
decisive indices, because they may be influenced by other 
factors, and because their sensitivity and specificity has 
never been formally assessed.
 An underappreciated, but interesting diagnostic pa-
rameter is uric acid. As mentioned, low uric acid levels 
are associated with volume expansion in general and 
SIAD in particular (except in the elderly)  [22] . Volume 
expansion increases uric acid clearance and reduces its 
reabsorption secondary to a reduction in proximal sodi-
um reabsorption. Furthermore, stimulation of the V1a 
Table 1. Diagnostic considerations in the approach to hyponatre-
mia
1 In acute and symptomatic hyponatremia, therapy precedes 
diagnosis
2 The symptoms of hyponatremia are: nausea and vomiting 
(<136 mmol/l), cognitive impairment (<136 mmol/l),
confusion (<131 mmol/l), seizures (<125 mmol/l),
noncardiogenic pulmonary edema (<125 mmol/l),
coma (<117 mmol/l), and death (depending on therapy)
3 Chronic hyponatremia is also associated with other neuro-
logical impairments, such as falls, gait disturbances, and
attention deficits
4 Pseudohyponatremia (still possible with ion-selective
electrodes) and hyperglycemia-induced hyponatremia should 
be considered early during the diagnostic process
5 Hyponatremia usually means high vasopressin levels – the
diagnostic process should focus on the reason why these levels 
are elevated
6 The clinical assessment of the extracellular fluid volume 
should not be a determining factor in the differentiation of 
hyponatremia
7 Hypopituitarism and primary adrenal insufficiency are often 
overlooked, the latter because hyperkalemia may be absent 
and random cortisol levels may be normal
8 The syndrome of inappropriate antidiuresis should only be
diagnosed after excluding diuretic use, thyroid, adrenal, and 
pituitary insufficiency
9 If all else fails, calculate a ‘tonicity balance’ with separate mass 
balances for water and sodium plus potassium
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receptor may also contribute to renal uric acid loss, be-
cause in experimental hyponatremia, hypouricemia is 
less pronounced when it is induced by V2R-specific stim-
ulation (using dDAVP) compared to stimulation of both 
the V1a and V2 receptors  [33] . In addition, Maesaka et al. 
[34, 35] have advocated the diagnostic value of uric acid 
in the differentiation between hyponatremia due to SIAD 
and hyponatremia due to renal salt wasting. The response 
to treatment may differentiate the two underlying disor-
ders because in their case series water restriction correct-
ed both hypouricemia and hyponatremia in SIAD, where-
as isotonic fluid resuscitation corrected hyponatremia, 
but not hypouricemia in renal salt wasting. According to 
Maesaka et al. [34, 35] , the basis of renal sodium (and uric 
acid) wasting in these patients was a (partial) Fanconi 
syndrome, as it was also associated with phosphaturia.
 Another critique on the existing clinical diagnostic 
algorithms for hyponatremia is their emphasis on the 
assessment of the ECF, while any proven reliability in 
the literature is lacking. For example, Chung et al.  [36] 
showed that the clinical assessment of hyponatremic pa-
tients correctly identified only 47% of hypovolemic pa-
tients, and 48% of normovolemic patients. In a system-
atic review, McGee et al.  [37] showed that the diagnostic 
accuracy of physical signs varied greatly for hypovole-
mia not due to blood loss. Few physical signs had proven 
utility, and an analysis based on serum electrolytes, cre-
atinine, and urea seemed superior  [37] . Our opinion is 
that the extracel lular volume status should still be rou-
tinely assessed in patients with hyponatremia, but that 
this information should not be the first or a determining 
factor, as is currently the case in many algorithms  [4, 
38] .
 Finally, when several diagnostic approaches have been 
fruitless and hyponatremia is still unexplained (a famil-
iar situation for many physicians), another useful ap-
proach may be to pursue a quantitative analysis by calcu-
lating separate mass balances for water and sodium plus 
potassium in a so-called ‘tonicity balance’  [39] .
 The Hyponatremias: Overview of Hyponatremic 
Disorders 
 Below a synopsis of the main hyponatremic syndromes 
is provided.
 Pseudohyponatremia 
 Pseudohyponatremia may still occur despite the use of 
ion-selective electrodes  [40] . Two of the three methods 
for determining the serum sodium concentration (flame 
photometry and indirect potentiometry) use sample dilu-
tion, which can artefactually lower the serum sodium 
concentration in situations when serum water is dis-
placed by elevated concentrations of lipids or proteins 
 [41] . Clinically, pseudohyponatremia can therefore occur 
during conditions such as hyperlipemic pancreatitis, 
multiple myeloma, or even hypercholesterolemia  [40] . 
Measuring serum osmolality and arterial serum sodium 
using a blood gas analyzer (direct potentiometry without 
sample dilution) are two ways to assess whether pseudo-
hyponatremia is present.
 Hyperglycemia-Induced Hyponatremia 
 Glucose is an effective osmole, and can therefore at-
tract water from the intracellular to the extracellular 
Table 2. Useful diagnostic parameters in the differentiation of 
hyponatremia
Diagnostic 
parameter
Interpretation
Serum osmolality
High Hyperglycemia, glycine solutions
Normal Pseudohyponatremia
Low Hypotonic hyponatremia
Urine osmolality
High1 Vasopressin-dependent cause of hyponatremia
Low1 Vasopressin-independent cause of hyponatremia
Urine sodium
Low Heart or liver failure, polydipsia, non-renal 
sodium loss, true volume depletion
High Diuretics, cerebral and renal salt wasting, SIAD, 
primary adrenal insufficiency, hypopituitarism
Serum potassium
Low Diuretic use, vomiting, diarrhea
High Primary adrenal insufficiency, renal failure
Serum urea
Low SIAD, acute volume expansion
Serum uric acid
Low SIAD, renal salt wasting, acute volume expansion
Alkalosis
Metabolic Diuretic use, vomiting
Respiratory Hypopituitarism
Acidosis
Metabolic Primary adrenal insufficiency, diarrhea, renal 
failure
1 Compared to serum osmolality.
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compartment. The early recognition of hyperglycemia-
induced hyponatremia is important because the shift of 
water is exactly opposite to most of the other hypona-
tremic disorders. Correction factors exist to assess if the 
degree of hyperglycemia can explain the degree of hypo-
natremia, and the ones reported vary between a 1.6-
and 2.4-mmol/l fall in natremia for every 5 mmol/l rise 
in glycemia  [42] .
 Diuretic-Induced Hyponatremia 
 Diuretic-induced hyponatremia is probably the most 
common hyponatremic disorder encountered in clinical 
medicine, and is mainly associated with the use of thia-
zide diuretics. Although the inhibition of the sodium-
chloride co-transporter by thiazides and the consequent 
renal sodium loss and volume depletion obviously con-
tribute to hyponatremia, it is not the only factor. This is 
illustrated by the fact that patients with Gitelman’s syn-
drome, who have an inactivating mutation of the trans-
porter, do not exhibit hyponatremia. Although this may 
be chronic adaptation, there is also evidence that thia-
zides may directly stimulate the non-osmotic release of 
vasopressin  [43] . Risk factors for thiazide-induced hypo-
natremia are age (although not a risk factor according to 
Sonnenblick et al.  [44] ), gender, hypokalemia, and a low 
lean body mass, while the concomitant use of loop diuret-
ics, angiotensin-converting enzyme inhibitors, or non-
steroidal anti-inflammatory drugs were not identified as 
risk factors  [44, 45] . Interestingly, Friedman et al.  [46] 
showed that a single dose of a thiazide diuretic may pre-
dict the development of hyponatremia because it pro-
duced a 5.5-mmol/l fall in serum sodium associated with 
weight gain in patients with thiazide-induced hyponatre-
mia compared to a 1.2- and 1.8-mmol/l fall in serum
sodium and weight loss in healthy controls or elderly hy-
pertensive patients.
 Syndrome of Inappropriate Antidiuresis 
 As discussed in a recent review  [21] , the causes of SIAD 
are myriad, and for the sake of clarity they are best cate-
gorized into pulmonary disorders, malignant diseases, 
disorders of the nervous system, and drug-induced SIAD. 
Robertson  [47] identified four patterns of SIAD including 
unregulated vasopressin secretion, elevated basal secre-
tion of vasopressin despite normal regulation by osmo-
larity, a ‘reset osmostat’ (described in pregnancy, cancer, 
psychosis, malnourishment, and tuberculosis), and un-
detectable vasopressin levels, as is found in nephrogenic 
SIAD.
 Nephrogenic SIAD 
 A conceptually interesting and novel hyponatremic 
disorder was recently described in two male children by 
Feldman et al. [15] ; it was caused by an activating muta-
tion of the V2R. The two children presented with the phe-
notype of classic SIAD (hyponatremia, high urinary so-
dium and osmolality, normovolemia), but without de-
tectable vasopressin levels. Since this initial discovery, 
the responsible activating missense mutation R137C has 
also been identified in pediatric and adult males and fe-
males  [31] . Nephrogenic SIAD should therefore be sus-
pected in any patient with therapy-resistant hyponatre-
mia, undetectable vasopressin levels, unresponsiveness 
to vasopressin-receptor antagonists and an abnormal re-
sponse to a water-loading test ( fig. 3 B).
 Cerebral Salt Wasting 
 Cerebral salt wasting is incompletely understood, but 
the best data on the possible mechanisms come from 
Berendes et al. [48] who compared patients who had sur-
gery for subarachnoid hemorrhage to patients who had 
brain tumor surgery. Postoperatively, subarachnoid hem-
orrhage patients developed polyuria and a natriuresis 
that correlated with increased B-type natriuretic peptide 
levels. Throughout the postoperative course, B-type na-
triuretic peptide was elevated, while aldosterone was sup-
pressed, both contributing to the natriuresis. Vasopressin 
levels were only briefly elevated, both before and after 
surgery. Intriguingly, none of the patients developed hy-
ponatremia, which was attributed to tailored saline re-
suscitation. This emphasizes that hyponatremia is not a 
prerequisite for the diagnosis cerebral salt wasting, but 
may be more the result of inadequate fluid manage-
ment.
 Hypopituitarism and Primary Adrenal Insufficiency 
 Hypopituitarism and primary adrenal insufficiency 
(Addison’s disease) are rare but often missed causes of 
hyponatremia. Hypopituitarism causes hyponatremia 
primarily because adrenocorticotropin hormone defi-
ciency causes cortisol deficiency which in turn can cause 
the inappropriate secretion of vasopressin. In primary 
adrenal deficiency, not only cortisol deficiency but also 
aldosterone deficiency contribute to hyponatremia, 
which is why hyperkalemia may also be present. Hypopi-
tuitarism can be caused by pituitary or hypothalamic dis-
eases (tumors, trauma, infection, infarction, radiation, 
surgery). Primary adrenal insufficiency is often caused 
by autoimmune adrenalitis, but can also be caused by de-
struction of the adrenal glands by a metastasis or adrenal 
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infections, for example in the acquired immunodeficien-
cy syndrome  [27] .
 Hyponatremia in Heart and Liver Failure 
 Heart failure (low cardiac output) or liver failure (sys-
temic vasodilatation) both lead to a low effective arterial 
blood volume  [49, 50] . As a response to the reduced baro-
receptor activity, the renin angiotensin system is activat-
ed first, whereas the vasopressin axis is activated after a 
greater decrease in arterial filling. The development of 
hyponatremia during heart or liver failure is a poor prog-
nostic sign, and hyponatremia has emerged as an inde-
pendent predictor for mortality from several epidemio-
logical studies  [51, 52] . Interestingly, hyponatremia was 
recently also found to be a predictor of long-term mortal-
ity and admission for heart failure after hospital dis-
charge in survivors of acute ST-elevation myocardial in-
farction  [53] . The explanation for these associations is 
probably not so much a direct effect of hyponatremia, but 
rather hyponatremia being a marker for the extent of the 
so-called ‘neurohumoral response’, and therefore the de-
gree of decompensation. The central role of hyponatre-
mia in this neurohumoral response has clearly been dem-
onstrated in heart and liver failure, in which hyponatre-
mia correlated with the activity of the renin angiotensin 
and prostaglandin systems  [54, 55] . The neurohumoral 
response probably also explains why a deterioration of 
hyponatremia in heart and liver failure coincides with a 
deterioration in renal function  [56] .
 Exercise-Associated Hyponatremia 
 Although the first report of exercise-associated hypo-
natremia dates from 1985  [57] , there has been renewed 
attention to this disorder since Almond et al.  [58] report-
ed a 13% incidence of hyponatremia in runners of the 
Boston marathon. An even larger and perhaps mechanis-
tically more interesting study was performed by Noakes 
et al.  [59] who measured post-race body weight changes 
in 2,153 athletes. Based on their data, three independent 
biological mechanisms for exercise-associated hypona-
tremia were postulated, namely excessive fluid intake, in-
appropriate vasopressin activity, and interactions be-
tween osmotically active and inactive sodium stores. Ex-
cessive fluid intake may represent learned behavior to 
prevent ‘dehydration’, or it could be the result of true 
thirst, for example because of high angiotensin II or low 
potassium levels (both reported during exercise and both 
strong thirst stimuli  [60] ). An interesting novel explana-
tion for inappropriate vasopressin excretion during exer-
cise was recently described by Siegel et al. [61] who re-
ported a fortyfold increase in interleukin-6 in marathon 
runners, which can directly stimulate vasopressin release 
 [16] . The evidence for a role of osmotically inactive so-
dium stores comes from the fact that 70% of the athletes 
in the study by Noakes et al.  [59] , who overconsumed hy-
potonic fluids, increased body weight without becoming 
hyponatremic. A possible explanation could be the os-
motic activation of sodium from exchangeable stores or 
the ability to prevent or undo the inactivation of sodium 
during exercise  [59] .
 Polydipsia and Low Solute Intake 
 The pathophysiology of the remaining hyponatremic 
disorders, water polydipsia, beer polydipsia, and hypona-
tremia due to a low dietary solute intake (‘tea and toast’), 
is independent of vasopressin ( fig. 3 B). Instead, their 
pathophysiology is explained by polydipsia in combina-
tion with solute loss or low solute intake. Thaler et al.  [62] 
demonstrated that electrolyte-free water excretion de-
pends not only on the osmolality and sodium plus potas-
sium content of the urine, but also on the total rate of 
solute excretion. Therefore, during a low dietary solute 
intake, solute excretion (mainly urea) can become the 
rate-limiting step for electrolyte-free water excretion. In 
this situation, amounts of fluid that are below the water 
excretory capacity of the kidneys (15–20 liters/day) can 
already cause hyponatremia. Similarly, Musch et al.  [63] 
demonstrated that in hyponatremia due to polydipsia, 
water intake alone was insufficient to explain the degree 
of hyponatremia, and that the apparent loss of solutes 
(possibly through an unknown renal route) played a sig-
nificant contributory role.
 Treating Hyponatremia 
 Acute hyponatremia should be treated swiftly to pre-
vent cerebral edema, while chronic hyponatremia should 
be treated slowly to avoid the osmotic demyelination syn-
drome  [2] . Despite the elegant simplicity of this adage, 
correcting hyponatremia is like sailing between Scylla 
and Charybdis because the acuity of hyponatremia is of-
ten unknown, both slow and rapid correction of hypona-
tremia can cause serious neurological damage, and there 
are no results from randomized clinical trials to guide the 
treatment of hyponatremia  [21, 38] . Second best are there-
fore authority-based guidelines, which advise to correct 
acute hyponatremia with 1–2 mmol/l/h until symptoms 
abate, but not to exceed an 8–10 mmol/l rise for the first 
24 h, and 18–25 mmol/l for the first 48 h  [21] . Chronic 
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hyponatremia should be corrected more slowly, especial-
ly when risk factors for osmotic demyelination are pres-
ent such as malnourishment or hypokalemia  [64] . How-
ever, chronic hyponatremia is not benign and has lost
its ‘innocence’ especially since Decaux  [65] asked the 
cryptic question, ‘Is asymptomatic hyponatremia really 
asymptomatic?’ In arguably one of the most important 
studies on hyponatremia in years, they showed in a 1: 2 
matched case-control study that chronic hyponatremia 
was associated with a fourfold increase in falls, and 
marked gait and attention impairments  [66] . Interesting-
ly, the authors postulated that these more subtle neuro-
logical symptoms could result from nerve conduction ve-
locity slowing, possibly brought about by a lower electro-
chemical gradient due to hyponatremia  [66] .
 The armamentarium for hyponatremia consists of iso-
tonic saline, hypertonic saline, water restriction, de-
meclocycline, urea, and the recently introduced vaso-
pressin receptor antagonists ( table 3 )  [67] . Furthermore, 
furosemide is often used in combination with one of 
these therapies to treat volume expansion and stimulate 
free water clearance. Paradoxically, vasopressin can also 
be added to the list if the rate of correction is too rapid 
and needs to be curtailed. The selection of therapy obvi-
ously depends on the underlying hyponatremic disorder. 
Hypertonic saline is most commonly used to correct 
acute hyponatremia with cerebral edema regardless of 
the underlying cause, whereas isotonic saline is often 
used in cases of ‘depletional’ hyponatremia. Water re-
striction, demeclocycline, and urea are recognized thera-
pies for SIAD, while the vasopressin receptor antagonists 
(also called ‘vaptans’ or ‘aquaretics’) have also been reg-
istered for SIAD, as well as hyponatremia in heart or liv-
er failure.
 To date, four vasopressin receptor antagonists have 
been developed, including satavaptan, lixivaptan, tolvap-
tan, and conivaptan, the latter of which also has V1a an-
tagonistic properties  [21] . Recently, several studies have 
shown their efficacy in correcting hyponatremia due to 
SIAD, heart failure, and liver failure. For example, in the 
SALT study, tolvaptan produced a rise in serum sodium 
concentration from approximately 128 to 136 mmol/l in 
10 days in patients with SIAD, heart failure, and liver fail-
ure (vs. a surprising rise with placebo from 128 to 132 
mmol/l)  [68] . A health survey also showed mental but not 
physical benefits of the drug  [68] . In the larger EVEREST 
trial tolvaptan was given to over 4,000 patients with heart 
failure in addition to standard therapy, and resulted in 
weight reduction, a 2–3-mmol/l increase in serum sodi-
um, more self-reported relief of dyspnea, but no effect on 
mortality  [69] .
 Several formulae exist to calculate the desired correc-
tion rate [for a recent review see  21 ]. The advantage of the 
so-called Adrogue-Madias formula, which estimates the 
effect of 1 liter of a chosen infusate on the serum sodium 
concentration  [2] , is that this formula was recently tested 
in a prospective study and was found to predict the rise 
in the serum sodium concentration fairly well  [70] . An 
Table 3. Treatment of hyponatremia
Hyponatremic disorder Therapeutic options
Acute and symptomatic hyponatremia Regardless of cause: hypertonic saline
Thiazide-induced hyponatremia Isotonic saline, stop diuretic
Non-renal sodium loss (gastrointestinal disease, burns) Isotonic saline
Congestive heart failure Fluid restriction, vasopressin receptor antagonists
Liver cirrhosis Fluid restriction, vasopressin receptor antagonists
Adrenal insufficiency Isotonic saline, hydrocortisone
Hypothyroidism Thyroid hormone replacement
Cerebral salt wasting Isotonic saline
Syndrome of inappropriate antidiuresis (SIAD) Fluid restriction, demeclocycline, urea, -opioid agonist, vasopressin 
receptor antagonist1
Nephrogenic SIAD As SIAD. Especially urea appears effective 
Reset osmostat No treatment
Low solute intake Increased protein and electrolyte intake
Exercise associated hyponatremia If acute: hypertonic saline 
Primary polydipsia If acute: hypertonic saline. Prevention: clozapine
1 Some of these options may also be appropriate in other forms of hyponatremia with an increased extracellular fluid volume.
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important caveat is that the correction as calculated by 
this formula may be too rapid in patients with extracel-
lular volume depletion who can have sudden water diure-
sis when the stimulus for vasopressin release abates  [70] . 
To some extent, the rise in serum sodium concentration 
will always remain unpredictable, and therefore it is rec-
ommended not to rely too heavily on predictions based 
on formulas, but to select the appropriate therapy and 
monitor the serum sodium concentration, urine output 
and urine composition frequently.
 Perspectives 
 In the years to come, the long-term effects of vasopres-
sin receptor antagonists in the treatment of hyponatre-
mia will likely be one of the major topics. Despite their 
proven efficacy, it remains to be seen what their exact 
place in the treatment of hyponatremia will become, and 
their inclusion in treatment algorithms seems somewhat 
preliminary  [21] . It will be interesting to see whether they 
only increase the serum sodium level, or whether they 
also affect outcome in heart or liver failure, or whether 
they might expedite the duration of therapy. Still, their 
potential dangers should be borne in mind, including the 
risk of osmotic demyelination with sometimes uncon-
trollable rises in serum sodium concentration, and po-
tential untoward effects in patients with hypovolemic hy-
ponatremia  [71] . In addition to the concept of vasopressin 
receptor antagonists, it was of interest to learn that the 
V2R-AQP2 cascade ( fig. 1 ) can also be targeted from the 
other side by water channel antagonists. In experiments 
with oocytes, it was shown to be possible to inhibit the 
AQP water channels with quaternary ammonium com-
pounds, which could be of interest for the future treat-
ment of hyponatremia  [72] . Other interesting subjects for 
future research include the role of osmotically inactive 
sodium stores in water and sodium balance regulation 
 [59] , and the possible role of nerve conduction velocity 
slowing in the symptomatology of chronic hyponatremia 
 [66] . For the short term, the prevention of hyponatremia 
and the improvement in its management seem both nec-
essary and achievable goals, especially given the persis-
tently high rates of hospital-acquired hyponatremia with 
considerable morbidity and mortality  [1, 73] .
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